title: Dorsal hippocampus is necessary for novel learning but sufficient for subsequent similar learning.
abstract: Our current understanding of brain mechanisms involved in learning and memory has been derived largely from studies using experimentally naïve animals. However, it is becoming increasingly clear that not all identified mechanisms may generalize to subsequent learning. For example, N-methyl-D-aspartate glutamate (NMDA) receptors in the dorsal hippocampus are required for contextual fear conditioning in naïve animals but not in animals previously trained in a similar task. Here we investigated how animals learn contextual fear conditioning for a second time-a response which is not due to habituation or generalization. We found that dorsal hippocampus infusions of voltage-dependent calcium channel blockers or the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) agonist impaired the first, not the second contextual learning. Only manipulations of the entire hippocampus led to an impairment in second learning. Specifically, inactivation of either the dorsal or ventral hippocampus caused the remaining portion of the hippocampus to acquire and consolidate the second learning. Thus, dorsal hippocampus seems necessary for initial contextual fear conditioning, but either the dorsal or ventral hippocampus is sufficient for subsequent conditioning in a different context. Together, these findings suggest that prior training experiences can change how the hippocampus processes subsequent similar learning.
authors.affiliation: Department of Psychology, McGill University, Montreal, Canada H3A 1B1. s.wang@ed.ac.uk
authors.forename: Szu-Han
authors.initials: SH
authors.lastname: Wang
authors.forename: Peter S B
authors.initials: PS
authors.lastname: Finnie
authors.forename: Oliver
authors.initials: O
authors.lastname: Hardt
authors.forename: Karim
authors.initials: K
authors.lastname: Nader
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000494:pharmacology / Q000633:toxicity; D000647:Amnesia / Q000139:chemically induced / Q000503:physiopathology; D000818:Animals; D000841:Anisomycin / Q000494:pharmacology / Q000633:toxicity; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000633:toxicity; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology*; D004597:Electroshock; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000633:toxicity; D005239:Fear / Q000502:physiology*; D046352:Freezing Reaction, Cataleptic / Q000187:drug effects / Q000502:physiology; D018755:GABA Agonists / Q000494:pharmacology / Q000633:toxicity; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D008297:Male; D008959:Models, Neurological; D008960:Models, Psychological; D009118:Muscimol / Q000494:pharmacology / Q000633:toxicity; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology / Q000633:toxicity; D017207:Rats, Sprague-Dawley; D012153:Retention, Psychology / Q000187:drug effects / Q000502:physiology*; D014700:Verapamil / Q000494:pharmacology / Q000633:toxicity
chemical_list: D002121:Calcium Channel Blockers; D018691:Excitatory Amino Acid Antagonists; D018755:GABA Agonists; D011500:Protein Synthesis Inhibitors; C096637:2-amino-5-phosphono-3-pentenoic acid; D009118:Muscimol; D000841:Anisomycin; D015763:2-Amino-5-phosphonovalerate; D014700:Verapamil